Antiphospholipid syndrome (APS) with pleural effusion is extremely rare. A 75-year-old man was admitted to our hospital for spreading erythema on his trunk and extremities, as well as dyspnea. One year before admission, he had visited us with a 1-year history of erythema and purpura on his legs and occasional fever. Given the diagnosis of APS, we initiated a combination therapy of aspirin and warfarin, but the skin lesions had gradually worsened. A biopsy specimen revealed marked thrombosis in the dermal and subcutaneous small vessels. In addition, chest X-ray and computed tomography demonstrated a large pleural effusion in the left lung. He underwent repeated drainage of the pleural effusion but the effusion recurred. We added oral prednisolone 30 mg daily to his prior anticoagulant therapy. The skin lesions and pleural effusion rapidly improved and disappeared without any complication. Corticosteroids might be a choice of treatment for intractable pleural effusion in APS patients.
Introduction
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombosis and morbidity, specifically in pregnancy, due to antiphospholipid antibodies. About half of the cases of APS occur as a primary disorder, while the rest arise in association with other autoimmune diseases, such as systemic lupus erythematosus (SLE) [1] . Some diseases, such as pulmonary thrombosis and pulmonary hypertension, are known to be complicated by APS [2] ; however, APS with pleural effusion is extremely rare. Here, we present a case of APS complicated by unilateral pleural effusion that responded well to oral corticosteroid therapy.
Case Presentation
A 75-year-old Japanese man was admitted to our hospital for spreading erythema on his trunk and extremities, as well as dyspnea. One year prior to admission, he visited us with a 1-year history of erythema and purpura on his legs, accompanied by intermittent fever. Results of laboratory examinations for antiphospholipid antibodies, lupus anticoagulant (using the phospholipid neutralization test), and anticardiolipin antibody had been positive 12 weeks apart. In addition, he showed positive antinuclear antibody (1:80, homogeneous pattern), but was negative for anti-dsDNA antibody, anti-Sm antibody, anti-RNP antibody, anti-SS-A antibody, anti-SS-B antibody, antitopoisomerase I antibody, and anticentromere antibody. MPO-ANCA, PR3-ANCA, and cryoglobulin were negative. Given the diagnosis of APS, we initiated combination therapy with aspirin (100 mg daily) and warfarin (target international normalized ratio, 2.0-3.0), but the skin lesions continued to gradually worsen. Violaceous erythema, purpura, and pigmentation were widely noted on his trunk and extremities ( fig. 1 ); they were associated with low platelets (93,000/μl) and elevated partial thromboplastin time (48.4 s). A biopsy specimen revealed marked thrombosis in the dermal and subcutaneous small vessels ( fig. 2 ). There were interface changes of the dermoepidermal junction and mild inflammatory infiltrates in the perivascular area of the dermis, but mucin deposition and thickening of the basal layer of the epidermis were not apparent. In addition, a chest X-ray and computed tomography demonstrated a large pleural effusion in the left lung ( fig. 3 ), without evidence of large vessel thrombus. Electrocardiogram and echocardiogram were normal. Despite serial thoracenteses, effusion recurred. Thoracoscopy and parietal pleura biopsy showed only marked lymphocytic infiltration without evidence of malignancy. An analysis of the pleural fluid also indicated a benign exudative effusion. Bacterial and fungal cultures, as well as cytology analyses for malignant cells, were all negative. After excluding infectious diseases, malignancies, pulmonary thrombosis, and heart failure, we added oral prednisolone (30 mg daily) to his prior anticoagulant regimen. The skin lesions and the pleural effusion improved rapidly, eventually disappearing without complication ( fig. 4 ). On follow-up clinical examinations, no symptoms related to SLE or other collagen diseases were noted.
Discussion
The cause of the pleural effusion in this case continues to be unclear. Common causes of pleural effusion include malignancies, infectious diseases, pulmonary embolism, collagen vascular disease, and heart failure [3] . APS-related pleural effusion has rarely been reported, and those cases that have been reported appeared to be complications of accompanying pulmonary embolism, SLE, or catastrophic APS [4] [5] [6] . Pleuritis, which can induce pleural effusion, is the most common pleuropulmonary manifestation of SLE [7] . In the present case, after excluding these differential diagnoses, APS was determined to be the direct cause of the pleural effusion. However, a strong possibility still exists that the pleural effusion may be associated with occult collagen vascular disease, particularly SLE or lupus-like disease (LLD) heretofore undiagnosed. Several studies have suggested that patients with primary APS may develop SLE or LLD. A long-term follow-up study in 128 patients with primary APS demonstrated that 11 patients (8%) developed SLE, while 6 (5%) developed LLD during a median follow-up period of 8.2 years (range, 114 years) [8] . The results of this study suggest that the pleural effusion may be attributed to a coexisting condition like LLD, although our patient has not fulfilled American College of Rheumatology diagnostic SLE criteria to date. This may be supported by the fact that oral corticosteroid therapy was a remarkably effective treatment of the pleural effusion that had previously been unsuccessfully treated by anticoagulant therapy and repeated drainage.
Corticosteroids and immunosuppressants continue to be the treatment of choice for severe SLE complications, including pleural effusion [9] . Furthermore, the clinical manifestations of primary APS and APS associated with SLE are similar, which makes it more difficult to differentiate these diseases. As pleural effusion can be life-threatening, physicians should be aware of this entity. Corticosteroids might be an effective choice of treatment for intractable pleural effusion in APS patients. 
